Endovia Health Sciences, Inc.

EDVA

Börsenwert 1,62 Mio. $

FORT LAUDERDALE, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (“Endovia” or the “Company”) (NYSE American: EDVA), in association with Lupvindol BioSciences (“Lupvindol”), today announced that the U.S. Food and Drug Administration's (“FDA”) Center for Veterinary Medicine has determined that the proposed use of CannEpil®, an investigational cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oral solution, for the control of pain associated with bone cancer in dogs qualifies as a “minor use” under the Minor Use and Minor Species (“MUMS”) program.

Endovia financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines

FORT LAUDERDALE, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (NYSE American: EDVA), formerly Splash Beverage Group, Inc. (NYSE American: SBEV) ("Endovia Health" or the "Company") announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine has established Investigational New Animal Drug (INAD) File No.

FORT LAUDERDALE, Fla., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the “Company”) today announced that its corporate name will change to Endovia Health Sciences, Inc., and its common stock will begin trading on the NYSE American under the new ticker symbol “EDVA” effective at market open at 9:30 a.m.

FORT LAUDERDALE, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today reported financial results for the second quarter ended June 30, 2026, and provided an update on the Company's ongoing strategic transformation toward Endovia Health Sciences.

FORT LAUDERDALE, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the "Company") today announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 21, 2026.

Collaboration with Lupvindol Biosciences will initially target companion-animal oncology and chronic pain management Splash retains ownership of resulting data, intellectual property and commercialization rights FORT LAUDERDALE, Fla., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has entered into a strategic development and collaboration agreement with Lupvindol Biosciences Ltd.

Splash expands its exclusive global license for CannEpil® to include veterinary applications, creating a second regulated pharmaceutical development platfo

SPLASH announces significant actions designed to strengthen the Company's financial position and advance its previously announced NYSE compliance plan.

FORT LAUDERDALE, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) ("Splash," "Splash Beverage" or the "Company") today announced that NYSE American has accepted the Company's plan to regain compliance with the Exchange's continued listing standards and has granted the Company a compliance period through January 29, 2027.